** Morningstar analysts expect Telix Pharmaceuticals TLX.AX to receive a delayed regulatory approval, instead of a denial, for co's Pixclara, an imaging agent for glioma brain cancer
** Telix on Monday said that the U.S. Food and Drug Administration declined to approve its new drug application for Pixclara
** FDA has requested additional clinical evidence to progress the application
** Brokerage expects the product to make first sales and contribute to earnings from 2026, instead of 2025
** Adds, it sees no material effect on co over the medium term
** Stock rated "buy" on average; median price target stands at A$35, per data compiled by LSEG
** Stock last up 8.4% YTD
(Reporting by Jasmeen Ara Shaikh in Bengaluru)
((JasmeenAraIslam.Shaikh@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。